These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Pathomechanism of atopic diseases and new methods of their treatment]. Cichocka-Jarosz E; Nizankowska-Mogilnicka E Pol Arch Med Wewn; 2003 Jan; 109(1):61-9. PubMed ID: 12879768 [No Abstract] [Full Text] [Related]
9. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Leckie MJ; ten Brinke A; Khan J; Diamant Z; O'Connor BJ; Walls CM; Mathur AK; Cowley HC; Chung KF; Djukanovic R; Hansel TT; Holgate ST; Sterk PJ; Barnes PJ Lancet; 2000 Dec 23-30; 356(9248):2144-8. PubMed ID: 11191542 [TBL] [Abstract][Full Text] [Related]
10. Functional CD137 receptors are expressed by eosinophils from patients with IgE-mediated allergic responses but not by eosinophils from patients with non-IgE-mediated eosinophilic disorders. Heinisch IV; Bizer C; Volgger W; Simon HU J Allergy Clin Immunol; 2001 Jul; 108(1):21-8. PubMed ID: 11447378 [TBL] [Abstract][Full Text] [Related]
11. Anti-IL-5 monoclonal antibody inhibits allergic late phase bronchial eosinophilia in guinea pigs: a therapeutic approach. Chand N; Harrison JE; Rooney S; Pillar J; Jakubicki R; Nolan K; Diamantis W; Sofia RD Eur J Pharmacol; 1992 Jan; 211(1):121-3. PubMed ID: 1618260 [TBL] [Abstract][Full Text] [Related]
12. Airway hyperresponsiveness, late allergic response, and eosinophilia are reversed with mycobacterial antigens in ovalbumin-presensitized mice. Hopfenspirger MT; Agrawal DK J Immunol; 2002 Mar; 168(5):2516-22. PubMed ID: 11859146 [TBL] [Abstract][Full Text] [Related]
13. Interleukin 12 inhibits antigen-induced airway hyperresponsiveness, inflammation, and Th2 cytokine expression in mice. Gavett SH; O'Hearn DJ; Li X; Huang SK; Finkelman FD; Wills-Karp M J Exp Med; 1995 Nov; 182(5):1527-36. PubMed ID: 7595222 [TBL] [Abstract][Full Text] [Related]
14. [Anti-interleukin-5 therapy for eosinophilic diseases]. Simon D; Braathen LR; Simon HU Hautarzt; 2007 Feb; 58(2):122, 124-7. PubMed ID: 17221241 [TBL] [Abstract][Full Text] [Related]
15. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Egan RW; Athwal D; Bodmer MW; Carter JM; Chapman RW; Chou CC; Cox MA; Emtage JS; Fernandez X; Genatt N; Indelicato SR; Jenh CH; Kreutner W; Kung TT; Mauser PJ; Minnicozzi M; Murgolo NJ; Narula SK; Petro ME; Schilling A; Sehring S; Stelts D; Stephens S; Taremi SS; Zurcher J Arzneimittelforschung; 1999 Sep; 49(9):779-90. PubMed ID: 10514907 [TBL] [Abstract][Full Text] [Related]
16. Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5. Esnault S; Kelly EA Crit Rev Immunol; 2016; 36(5):429-444. PubMed ID: 28605348 [TBL] [Abstract][Full Text] [Related]
17. Inhibitory effect of the TRFK-5 anti-IL-5 antibody in a guinea pig model of asthma. Mauser PJ; Pitman A; Witt A; Fernandez X; Zurcher J; Kung T; Jones H; Watnick AS; Egan RW; Kreutner W Am Rev Respir Dis; 1993 Dec; 148(6 Pt 1):1623-7. PubMed ID: 7504892 [TBL] [Abstract][Full Text] [Related]
18. Regulatory role of antigen-induced interleukin-10, produced by CD4(+) T cells, in airway neutrophilia in a murine model for asthma. Nabe T; Ikedo A; Hosokawa F; Kishima M; Fujii M; Mizutani N; Yoshino S; Ishihara K; Akiba S; Chaplin DD Eur J Pharmacol; 2012 Feb; 677(1-3):154-62. PubMed ID: 22209878 [TBL] [Abstract][Full Text] [Related]
19. Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Molfino NA; Gossage D; Kolbeck R; Parker JM; Geba GP Clin Exp Allergy; 2012 May; 42(5):712-37. PubMed ID: 22092535 [TBL] [Abstract][Full Text] [Related]
20. Cytokines and their receptors as therapeutic targets in asthma. Pauwels RA; Brusselle GG; Tournoy KG; Lambrecht BN; Kips JC Clin Exp Allergy; 1998 Aug; 28 Suppl 3():1-5. PubMed ID: 9756180 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]